ROIV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ROIV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Roivant Sciences's 1-Year ROIIC % for the quarter that ended in Sep. 2024 was -48.28%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Roivant Sciences's 1-Year ROIIC % or its related term are showing as below:
The historical data trend for Roivant Sciences's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences Annual Data | |||||||||
Trend | Mar21 | Mar22 | Mar23 | Mar24 | |||||
1-Year ROIIC % | - | 1,226.89 | 58.74 | -56.40 |
Roivant Sciences Quarterly Data | ||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
1-Year ROIIC % | Get a 7-Day Free Trial | 201.09 | -282.73 | -56.40 | 1,731.02 | -48.28 |
For the Biotechnology subindustry, Roivant Sciences's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Roivant Sciences's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's 1-Year ROIIC % falls into.
Roivant Sciences's 1-Year ROIIC % for the quarter that ended in Sep. 2024 is calculated as:
1-Year ROIIC % | = | 1-Year Incremental Net Operating Profit After Taxes (NOPAT)** | / | 1-Year Incremental Invested Capital |
= | ( -1089.2963 (Sep. 2024) - -979.5624 (Sep. 2023) ) | / | ( 857.998 (Sep. 2024) - 630.725 (Sep. 2023) ) | |
= | -109.7339 | / | 227.273 | |
= | -48.28%*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Roivant Sciences (NAS:ROIV) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Thank you for viewing the detailed overview of Roivant Sciences's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric Venker | officer: President & COO | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
Daniel Allen Gold | director | 6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119 |
Qvt Financial Lp | 10 percent owner, other: Director by Deputization | 888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106 |
Keith S Manchester | director | C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L |
Rakhi Kumar | officer: Chief Accounting Officer | C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043 |
Matthew Gline | director, officer: CEO | C/O UROVANT SCIENCES, INC., 5151 CALIFORNIA AVENUE, SUITE 250, IRVINE CA 92617 |
Svf Investments (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET, LONDON X0 W1K3JP |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Performance Llc | 10 percent owner | 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020 |
Viking Global Opportunities Parent Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Softbank Vision Fund L.p. | 10 percent owner | AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH |
Meghan Fitzgerald | director | C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511 |
Richard Pulik | officer: CFO | SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB |
Vivek Ramaswamy | director | C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902 |
From GuruFocus
By Marketwired • 11-12-2024
By Marketwired • 12-03-2024
By Marketwired • 05-16-2024
By Marketwired • 08-08-2024
By Marketwired • 09-10-2024
By PRNewswire • 03-26-2024
By GuruFocus News • 11-05-2024
By Marketwired • 09-09-2024
By GuruFocus Research • 08-08-2024
By GuruFocus Research • 09-27-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.